TEVA:NYSETeva Pharmaceutical Industries Limited Analysis

Technical outlook: TEVA trades at $34.56, just below its 20‑day SMA of $35.10 but comfortably above the 50‑day ($32.27) and 200‑day ($27.48) averages, indicating a short‑term pull‑back within a longer‑term uptrend. The RSI sits at 55, suggesting neutral momentum, while the MACD histogram is negative and the signal line is labeled “bearish,” pointing to potential downside pressure. Volume is decreasing and 30‑day volatility is high at ~39.8%, with a beta around 1.0, underscoring market sensitivity. Support is identified near $33.61 and resistance near $36.99, framing a narrow trading range.
Fundamental backdrop: The company delivers solid profitability—gross margin of 52%, operating margin of 19% and ROE of 21.6%—and generates $2.6 B of free cash flow. However, leverage is extreme (debt‑to‑equity ≈ 206%) and cash balances ($3.7 B) cover only a fraction of total debt ($16.9 B). Valuation is mixed: trailing P/E of 25.8 is modestly below the industry average of 27.4, forward P/E collapses to 11.1, yet the DCF‑derived fair value ($21.2) lies well under the current price, flagging possible overvaluation. Analyst consensus is a “strong buy” with a median target of $40, and recent news—Fitch’s upgrade to BBB‑, R&D leadership changes, and modest Q1 revenue growth (+2% YoY)—adds positive momentum.